Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

MORF

Morphic Holding Inc

Apr 25 • 04:00PM ET

27.98

Dollar change +0.29
Percentage change 1.05	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO SCHA VTWO LABU VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.38	Insider Own	22.64%	Shs Outstand	49.75M	Perf Week	1.71%
Market Cap	1.40B	Forward P/E	-	EPS next Y	-4.31	Insider Trans	-0.27%	Shs Float	38.71M	Perf Month	-14.64%
Income	-161.25M	PEG	-	EPS next Q	-0.97	Inst Own	84.39%	Short Float	16.15%	Perf Quarter	-4.57%
Sales	0.00M	P/S	-	EPS this Y	-9.58%	Inst Trans	-1.45%	Short Ratio	12.53	Perf Half Y	36.55%
Book/sh	13.25	P/B	2.11	EPS next Y	-9.68%	ROA	-28.67%	Short Interest	6.25M	Perf Year	-40.09%
Cash/sh	13.16	P/C	2.13	EPS next 5Y	-	ROE	-29.59%	52W Range	19.34 - 63.08	Perf YTD	-3.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-35.64%	ROI	-24.25%	52W High	-55.65%	Beta	1.47
Dividend TTM	-	Quick Ratio	38.17	Sales past 5Y	134.56%	Gross Margin	-109.40%	52W Low	44.64%	ATR (14)	1.48
Dividend Ex-Date	-	Current Ratio	38.17	EPS Y/Y TTM	-116.41%	Oper. Margin	-34296.74%	RSI (14)	37.32	Volatility	4.86% 4.80%
Employees	121	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.40	Target Price	56.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-0.54%	Payout	-	Rel Volume	1.56	Prev Close	27.69
Sales Surprise	-	EPS Surprise	3.70%	Sales Q/Q	-100.00%	Earnings	Apr 25 BMO	Avg Volume	498.95K	Price	27.98
SMA20	-7.02%	SMA50	-16.69%	SMA200	-21.12%	Trades		Volume	772,240	Change	1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-23	Initiated	Citigroup	Buy	$46
Sep-25-23	Reiterated	Stifel	Hold	$61 → $33
Sep-25-23	Downgrade	BTIG Research	Buy → Neutral
Aug-09-23	Downgrade	Stifel	Buy → Hold	$69 → $61
Sep-07-22	Initiated	Stifel	Buy	$44
Jul-20-22	Initiated	SVB Leerink	Outperform	$45
Mar-31-22	Initiated	Canaccord Genuity	Buy	$68
Feb-11-22	Initiated	BTIG Research	Buy	$64
Dec-08-21	Initiated	Wells Fargo	Overweight	$81
Oct-26-20	Initiated	RBC Capital Mkts	Outperform	$35
Jul-22-19	Initiated	Wells Fargo	Outperform
Jul-22-19	Initiated	Jefferies	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	BMO Capital Markets	Outperform	$30

Show Previous Ratings

Apr-25-24 01:53PM	MORF Stock Earnings: Morphic Holding Beats EPS for Q1 2024 (InvestorPlace)
08:37AM	Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review (GuruFocus.com)
07:00AM	Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 (GlobeNewswire)
Apr-24-24 12:00PM	What Makes Morphic (MORF) a New Buy Stock (Zacks)
Mar-20-24 01:57PM	MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF) (GlobeNewswire)
08:00AM	Loading…
Mar-19-24 08:00AM	Morphic Appoints Dr. Simon Cooper as Chief Medical Officer (GlobeNewswire)
Mar-05-24 04:05PM	Morphic to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-24 09:55AM	Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High? (Zacks)
Feb-22-24 07:00AM	Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023 (GlobeNewswire)
Feb-08-24 09:55AM	Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet (Zacks) +5.13%
Jan-18-24 01:04AM	Morphic Holding Inc CEO Praveen Tipirneni Sells 13,923 Shares (GuruFocus.com)
Jan-05-24 09:55AM	Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade (Zacks)
Jan-03-24 04:05PM	Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.57%
Dec-20-23 09:55AM	Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect? (Zacks) -5.01%
Dec-01-23 03:59PM	Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors (Business Wire)
09:55AM	Loading…
09:55AM	Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High? (Zacks)
Nov-15-23 09:55AM	Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet (Zacks)
Nov-10-23 08:00AM	Morphic to Present at November Investor Conferences (GlobeNewswire)
Nov-09-23 12:00PM	Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.27%
Nov-06-23 04:24PM	Morphic Corporation: Company Investigated by the Portnoy Law Firm (GlobeNewswire) -6.20%
Nov-03-23 08:46AM	Morphic Holding Inc (MORF) Reports Q3 2023 Loss of $36.2 Million, Ends Quarter with $725. ... (GuruFocus.com) +8.20%
07:00AM	Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
Oct-09-23 08:00AM	Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set (GlobeNewswire)
Sep-28-23 06:27AM	The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan (American City Business Journals)
Sep-26-23 04:10PM	Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence (GlobeNewswire) -7.82%
Sep-25-23 04:08PM	The Surprise That Prompted Morphic Therapeutic To Dump 55% Over Two Days (Investor's Business Daily) -36.91%
12:58PM	Morphic Therapeutic stock nosedives on disappointing trial data (American City Business Journals)
Sep-22-23 05:30PM	Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023 (GlobeNewswire) -28.64%
Sep-09-23 01:01PM	Morphic Holding Inc CFO and COO Marc Schegerin Sells 20,000 Shares (GuruFocus.com)
Aug-29-23 08:00AM	Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Aug-09-23 04:05PM	Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire) -6.63%
Aug-07-23 06:24AM	Morphic Holding, Inc.'s (NASDAQ:MORF) large institutional owners must be happy as stock continues to impress, up 4.4% over the past week (Simply Wall St.)
Aug-03-23 08:55AM	Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 (GlobeNewswire)
Jun-08-23 03:22PM	3 Stocks That Could Skyrocket by This Time Next Summer (InvestorPlace)
Jun-06-23 04:05PM	Morphic to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-26-23 03:31PM	Here's Why We're Not At All Concerned With Morphic Holding's (NASDAQ:MORF) Cash Burn Situation (Simply Wall St.)
May-22-23 05:23PM	Inside Scoop: 10 Mid-Cap Stocks with Recent Insider Purchases (Insider Monkey)
May-12-23 08:30AM	Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-11-23 08:00AM	Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis (GlobeNewswire)
May-07-23 07:40PM	Insiders Pour Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Steer Toward Them Too (TipRanks)
May-06-23 08:13AM	Morphic Holding Founder Acquires 16% More Stock \ (Simply Wall St.)
May-05-23 10:30AM	Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
09:23AM	Q1 2023 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 12:13AM	Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering (GlobeNewswire) +5.57%
May-02-23 04:02PM	Morphic Therapeutic Announces Proposed Public Offering (GlobeNewswire)
Apr-30-23 08:10AM	What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
Apr-29-23 08:25AM	3 Biotech Buyout Targets to Watch (Motley Fool)
Apr-27-23 06:10AM	The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio (Zacks)
Apr-26-23 07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 11:54AM	Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars (Benzinga) +7.28%
08:15AM	Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures (GlobeNewswire)
06:59AM	Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023 (GlobeNewswire)
Apr-24-23 04:01PM	Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023 (GlobeNewswire)
Apr-18-23 10:56AM	Morphic Holding (NASDAQ:MORF) delivers shareholders strong 41% CAGR over 3 years, surging 20% in the last week alone (Simply Wall St.)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-18-23 08:29AM	Some Analysts Just Cut Their Morphic Holding, Inc. (NASDAQ:MORF) Estimates (Simply Wall St.)
Mar-03-23 09:05AM	Morphic to Present at TD Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-24-23 05:26AM	Morphic Holding Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Feb-23-23 08:00AM	Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 (GlobeNewswire)
Feb-15-23 09:04AM	Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF) (Simply Wall St.)
Feb-14-23 08:00AM	Morphic to Present at SVB Leerink Global Healthcare Conference (GlobeNewswire) +5.49%
Jan-26-23 05:54AM	The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug (American City Business Journals)
Jan-13-23 07:26AM	Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains? (Zacks)
Jan-05-23 09:09AM	Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 06:48AM	Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation (Simply Wall St.)
Nov-22-22 08:00AM	Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-09-22 08:00AM	Morphic Announces Participation in 2022 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 06:29AM	Industry Analysts Just Made An Upgrade To Their Morphic Holding, Inc. (NASDAQ:MORF) Revenue Forecasts (Simply Wall St.)
Nov-02-22 09:15AM	Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022 (GlobeNewswire)
Oct-28-22 12:07PM	Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance (Zacks) +7.22%
Oct-27-22 12:26PM	BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View (Zacks)
Oct-25-22 04:05PM	Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022 (GlobeNewswire) +9.13%
01:59PM	Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook (Zacks)
Oct-24-22 08:00AM	Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections (GlobeNewswire)
Oct-20-22 01:19PM	Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab (Zacks)
Oct-10-22 08:00AM	Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022 (GlobeNewswire)
Sep-30-22 01:20PM	Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate (Zacks)
10:22AM	Those who invested in Morphic Holding (NASDAQ:MORF) three years ago are up 66% (Simply Wall St.)
Sep-29-22 12:00PM	EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster (Zacks)
10:15AM	Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last? (Zacks)
Sep-28-22 12:00PM	Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree (GlobeNewswire) +7.31%
Sep-27-22 12:46PM	Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids (Zacks) +6.22%
Sep-26-22 12:39PM	Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why (Zacks)
11:17AM	AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication (Zacks)
Sep-23-22 11:14AM	Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris (Zacks)
11:02AM	Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK (Zacks)
Sep-22-22 01:28PM	Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors (Zacks)
Sep-21-22 11:44AM	AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID (Zacks)
07:00AM	Morphic Celebrates Foundational Integrin Research Published in Cell (GlobeNewswire)
Sep-20-22 12:10PM	AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication (Zacks)
Sep-19-22 12:28PM	Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia (Zacks)
12:21PM	Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids (Zacks)
Sep-16-22 11:42AM	Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal (Zacks)
Sep-15-22 12:15PM	J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up (Zacks)
11:54AM	Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine (Zacks)
Sep-14-22 01:33PM	Key Factors Driving Merck's (MRK) Outperformance This Year (Zacks)

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rogers Bruce	PRESIDENT	Mar 27 '24	Option Exercise	4.32	7,400	31,932	149,883	Mar 28 07:00 PM
Tipirneni Praveen P.	CEO	Jan 16 '24	Sale	27.49	13,923	382,753	42,013	Jan 17 07:04 PM
Rogers Bruce	President	Jan 16 '24	Sale	27.49	6,314	173,576	142,036	Jan 17 07:02 PM
SCHEGERIN MARC	CFO and COO	Jan 16 '24	Sale	27.49	6,041	166,071	37,460	Jan 17 07:03 PM
Farrell Robert E Jr	SVP Finance and CAO	Jan 16 '24	Sale	27.49	5,089	139,900	34,992	Jan 17 07:01 PM
DeVaul William	General Counsel and Secretary	Jan 16 '24	Sale	27.49	4,509	123,956	23,029	Jan 17 07:00 PM
Farrell Robert E Jr	SVP Finance and CAO	Jan 14 '24	Option Exercise	0.00	3,470	0	40,081	Jan 17 07:01 PM
DeVaul William	General Counsel and Secretary	Jan 14 '24	Option Exercise	0.00	3,250	0	27,538	Jan 17 07:00 PM
Rogers Bruce	President	Jan 14 '24	Option Exercise	0.00	5,070	0	148,350	Jan 17 07:02 PM
SCHEGERIN MARC	CFO and COO	Jan 14 '24	Option Exercise	0.00	4,690	0	43,501	Jan 17 07:03 PM
Tipirneni Praveen P.	CEO	Jan 14 '24	Option Exercise	0.00	12,500	0	55,936	Jan 17 07:04 PM
Tipirneni Praveen P.	CEO	Jan 13 '24	Option Exercise	0.00	29,500	0	43,436	Jan 17 07:04 PM
SCHEGERIN MARC	CFO and COO	Jan 13 '24	Option Exercise	0.00	14,675	0	38,811	Jan 17 07:03 PM
Rogers Bruce	President	Jan 13 '24	Option Exercise	0.00	15,225	0	143,280	Jan 17 07:02 PM
DeVaul William	General Counsel and Secretary	Jan 13 '24	Option Exercise	0.00	10,950	0	24,288	Jan 17 07:00 PM
Farrell Robert E Jr	SVP Finance and CAO	Jan 13 '24	Option Exercise	0.00	12,675	0	36,611	Jan 17 07:01 PM
SLATTERY JOSEPH P	Director	Nov 13 '23	Buy	20.60	2,400	49,436	9,066	Nov 14 07:04 PM
Edwards Martin	Director	Nov 13 '23	Buy	20.54	2,376	48,803	2,376	Nov 15 07:00 PM
SCHEGERIN MARC	CFO and COO	Sep 07 '23	Option Exercise	15.00	20,000	300,000	44,136	Sep 08 07:00 PM
SCHEGERIN MARC	CFO and COO	Sep 07 '23	Sale	54.34	20,000	1,086,849	24,136	Sep 08 07:00 PM
Tipirneni Praveen P.	President and CEO	Aug 01 '23	Option Exercise	4.32	3,597	15,539	17,533	Aug 03 06:58 PM
Tipirneni Praveen P.	President and CEO	Aug 01 '23	Sale	57.04	3,597	205,187	13,936	Aug 03 06:58 PM
Tipirneni Praveen P.	President and CEO	Jul 03 '23	Option Exercise	4.32	3,597	15,539	17,533	Jul 06 07:02 PM
Tipirneni Praveen P.	President and CEO	Jul 03 '23	Sale	57.04	3,597	205,178	13,936	Jul 06 07:02 PM
Tipirneni Praveen P.	President and CEO	Jun 12 '23	Option Exercise	4.32	840	3,629	14,776	Jun 14 07:04 PM
Tipirneni Praveen P.	President and CEO	Jun 12 '23	Sale	63.01	840	52,929	13,936	Jun 14 07:04 PM
DeVaul William	General Counsel and Secretary	Jun 07 '23	Sale	60.05	7,756	465,742	13,338	Jun 09 07:00 PM
Tipirneni Praveen P.	President and CEO	Jun 01 '23	Option Exercise	4.32	3,597	15,539	17,533	Jun 02 07:01 PM
Tipirneni Praveen P.	President and CEO	Jun 01 '23	Sale	57.14	3,597	205,519	13,936	Jun 02 07:01 PM
DeVaul William	General Counsel and Secretary	May 24 '23	Sale	60.00	100	6,000	21,094	May 25 08:44 PM
Farrell Robert E Jr	SVP Finance and CAO	May 23 '23	Option Exercise	4.32	10,000	43,200	33,708	May 25 08:45 PM
Farrell Robert E Jr	SVP Finance and CAO	May 23 '23	Sale	60.00	10,000	600,000	23,708	May 25 08:45 PM
DeVaul William	General Counsel and Secretary	May 23 '23	Sale	60.03	3,802	228,236	21,194	May 25 08:44 PM
Farrell Robert E Jr	SVP Finance and CAO	May 08 '23	Option Exercise	4.32	11,486	49,620	23,708	May 10 07:02 PM
Rogers Bruce	President	May 05 '23	Option Exercise	4.32	16,000	69,042	133,055	May 09 07:03 PM
Tipirneni Praveen P.	President and CEO	May 03 '23	Option Exercise	4.32	3,597	15,539	17,533	May 05 07:15 PM
SPRINGER TIMOTHY A	Director	May 03 '23	Buy	45.00	1,050,000	47,250,000	2,768,464	May 04 07:06 PM
Tipirneni Praveen P.	President and CEO	May 03 '23	Sale	51.11	3,597	183,857	13,936	May 05 07:15 PM

Open in Screener

KRON

Kronos Bio Inc

Apr 25 • 04:00PM ET

0.9800

Dollar change +0.0200
Percentage change 2.08	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-1.95	Insider Own	33.32%	Shs Outstand	58.95M	Perf Week	-4.85%
Market Cap	58.89M	Forward P/E	-	EPS next Y	-1.72	Insider Trans	8.93%	Shs Float	40.07M	Perf Month	-17.65%
Income	-112.67M	PEG	-	EPS next Q	-0.45	Inst Own	31.03%	Short Float	1.65%	Perf Quarter	-15.52%
Sales	6.29M	P/S	9.36	EPS this Y	13.46%	Inst Trans	-2.16%	Short Ratio	1.79	Perf Half Y	12.64%
Book/sh	2.70	P/B	0.36	EPS next Y	-2.12%	ROA	-44.34%	Short Interest	0.66M	Perf Year	-26.32%
Cash/sh	2.88	P/C	0.34	EPS next 5Y	-	ROE	-55.84%	52W Range	0.73 - 2.29	Perf YTD	-21.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-72.78%	ROI	-61.08%	52W High	-57.21%	Beta	1.87
Dividend TTM	-	Quick Ratio	7.24	Sales past 5Y	0.00%	Gross Margin	47.19%	52W Low	34.06%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	7.24	EPS Y/Y TTM	17.69%	Oper. Margin	-1891.38%	RSI (14)	36.27	Volatility	6.99% 8.11%
Employees	63	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-1791.87%	Recom	1.00	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	22.73%	Payout	-	Rel Volume	2.11	Prev Close	0.96
Sales Surprise	49.90%	EPS Surprise	18.10%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	370.24K	Price	0.98
SMA20	-13.92%	SMA50	-14.10%	SMA200	-22.17%	Trades		Volume	765,478	Change	2.08%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-14-22	Initiated	Berenberg	Buy	$12
Oct-20-21	Resumed	Cowen	Outperform
Jun-24-21	Initiated	H.C. Wainwright	Buy	$35
Nov-03-20	Initiated	Piper Sandler	Overweight	$50
Nov-03-20	Initiated	Jefferies	Buy	$36
Nov-03-20	Initiated	Goldman	Buy	$45
Nov-03-20	Initiated	Cowen	Outperform

Apr-24-24 04:01PM	Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-27-24 12:00PM	Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-21-24 01:53PM	KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:05AM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 04:05PM	Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway (GlobeNewswire) +7.50%
04:44PM	Loading…
Mar-05-24 04:44PM	Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting (GlobeNewswire)
Feb-27-24 04:05PM	Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference (GlobeNewswire) +11.40%
Jan-25-24 08:00AM	Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement (GlobeNewswire)
Dec-18-23 04:06PM	Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate (GlobeNewswire)
Dec-04-23 08:00AM	Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire)
Nov-27-23 04:05PM	Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-13-23 05:25PM	Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.51%
04:05PM	Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 04:05PM	Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study (GlobeNewswire) -5.10%
12:00PM	Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Oct-27-23 08:00AM	Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting (GlobeNewswire)
Oct-13-23 12:30PM	Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC (GlobeNewswire) -13.70%
Oct-04-23 04:05PM	Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13 (GlobeNewswire)
Aug-17-23 08:00AM	Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development (GlobeNewswire)
Aug-08-23 05:50PM	Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results (GlobeNewswire)
Jul-19-23 07:27AM	With 47% ownership, Kronos Bio, Inc. (NASDAQ:KRON) has piqued the interest of institutional investors (Simply Wall St.)
Jun-06-23 08:00AM	Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance (GlobeNewswire)
Jun-01-23 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-23 07:00AM	The past year for Kronos Bio (NASDAQ:KRON) investors has not been profitable (Simply Wall St.)
May-10-23 05:35PM	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results (GlobeNewswire)
Apr-24-23 04:05PM	Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors (GlobeNewswire)
Apr-18-23 02:24PM	Kronos Bio, Inc. (NASDAQ:KRON) insider upped their holding by 11% earlier this year (Simply Wall St.)
Apr-11-23 04:05PM	Kronos Bio Announces Changes to Board of Directors (GlobeNewswire)
04:05PM	Loading…
Mar-15-23 04:05PM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results (GlobeNewswire) -5.66%
Feb-28-23 04:05PM	Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Jan-09-23 09:25AM	Deals, data kick off biotech's big JPM Week (American City Business Journals) +15.12%
08:23AM	Kronos Bios stock rallies after announcing drug-discovery deal with Roche (MarketWatch)
07:00AM	Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology (GlobeNewswire)
Dec-20-22 10:28AM	We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.) -5.19%
Dec-12-22 09:35AM	Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks (Zacks) +10.23%
Dec-11-22 10:00AM	Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting (GlobeNewswire)
Dec-07-22 04:05PM	Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-22-22 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
09:35AM	Here's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks (Zacks)
Nov-09-22 12:04PM	Insiders might want to re-evaluate their US$2.4m stock purchase as Kronos Bio, Inc. (NASDAQ:KRON) drops to US$145m (Simply Wall St.) -9.38%
Nov-08-22 04:10PM	Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results (GlobeNewswire)
04:05PM	Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742 (GlobeNewswire)
Oct-12-22 04:04AM	Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022 (GlobeNewswire)
Sep-06-22 04:05PM	Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-22-22 11:33AM	Kronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor (Benzinga) -6.10%
08:00AM	Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia (GlobeNewswire)
Aug-16-22 04:05PM	Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML (PR Newswire) -6.01%
Aug-09-22 09:55AM	Can Kronos Bio, Inc. (KRON) Climb 312% to Reach the Level Wall Street Analysts Expect? (Zacks) -9.47%
Aug-04-22 04:05PM	Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results (GlobeNewswire)
Jul-25-22 08:48AM	7 Nasdaq Stocks to Buy on the Dip (InvestorPlace)
Jul-10-22 10:27AM	We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.)
Jul-08-22 12:00PM	Kronos Bio, Inc. (KRON) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-10-22 03:04AM	Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress (GlobeNewswire) -13.07%
Jun-01-22 04:05PM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -7.26%
May-22-22 08:04AM	Norbert Bischofberger Is The President of Kronos Bio, Inc. (NASDAQ:KRON) And They Just Picked Up 11% More Shares (Simply Wall St.)
May-17-22 07:00AM	Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference (GlobeNewswire) +8.54%
May-12-22 10:23AM	Kronos Bios Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress (GlobeNewswire)
May-06-22 12:23PM	Could The Kronos Bio, Inc. (NASDAQ:KRON) Ownership Structure Tell Us Something Useful? (Simply Wall St.) -7.01%
May-04-22 04:05PM	Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results (GlobeNewswire)
Apr-08-22 01:07PM	Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR (GlobeNewswire)
Mar-08-22 05:08PM	Kronos Bios Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-01-22 07:00AM	Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-24-22 04:05PM	Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results (GlobeNewswire)
Feb-01-22 04:05PM	Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development (GlobeNewswire)
Jan-31-22 01:45PM	We're Not Very Worried About Kronos Bio's (NASDAQ:KRON) Cash Burn Rate (Simply Wall St.)
Dec-17-21 08:00AM	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies (PR Newswire) +9.14%
Dec-09-21 10:15AM	Kronos Bio Inc (KRON) President & CEO Norbert W Bischofberger Bought $173,564 of Shares (GuruFocus.com)
Dec-06-21 07:00AM	Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-21 07:00AM	Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742 (GlobeNewswire) -5.78%
Nov-24-21 07:00AM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-11-21 04:05PM	Kronos Bio Appoints Roshawn Blunt to Board of Directors (GlobeNewswire)
Nov-09-21 04:10PM	Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results (GlobeNewswire)
Nov-08-21 04:44PM	Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus Platform (GlobeNewswire)
Nov-04-21 07:00AM	Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology (GlobeNewswire)
Oct-11-21 09:41AM	Is Kronos Bio, Inc.'s (NASDAQ:KRON) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Oct-05-21 12:17PM	Chief Scientific Officer Of Kronos Bio Trades $220K In Company Stock (Benzinga)
Sep-30-21 04:36PM	Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021 (GlobeNewswire)
Sep-14-21 08:00AM	Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations (GlobeNewswire)
Sep-07-21 07:00AM	Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-12-21 04:05PM	Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results (GlobeNewswire)
Jul-27-21 05:36PM	Is Kronos Bio, Inc. (KRON) A Good Stock To Buy? (Insider Monkey)
08:00AM	Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML) (GlobeNewswire)
Jul-12-21 04:56AM	Have Insiders Been Buying Kronos Bio, Inc. (NASDAQ:KRON) Shares This Year? (Simply Wall St.)
May-26-21 08:00AM	Kronos Bio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-25-21 08:00AM	Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today (GlobeNewswire)
May-11-21 04:05PM	Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day (GlobeNewswire)
May-06-21 08:00AM	Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference (GlobeNewswire) -5.10%
Apr-11-21 05:53AM	What Type Of Shareholders Own The Most Number of Kronos Bio, Inc. (NASDAQ:KRON) Shares? (Simply Wall St.)
Apr-10-21 08:30AM	Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 (GlobeNewswire)
Mar-31-21 11:25AM	Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D. (GlobeNewswire) +5.10%
Mar-26-21 08:00AM	Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors (GlobeNewswire)
Mar-23-21 04:05PM	Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results (GlobeNewswire)
Mar-10-21 04:35PM	Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers (GlobeNewswire)
Mar-04-21 08:12AM	The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company (Benzinga)
07:00AM	Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML) (GlobeNewswire)
Feb-25-21 08:00AM	Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers (GlobeNewswire)
Feb-22-21 08:00AM	Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference (GlobeNewswire)
Jan-26-21 08:00AM	Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors (GlobeNewswire) -8.74%

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frisbee Allison	SR VP, CORP OPERATIONS & LEGAL	Feb 21 '24	Sale	1.05	12,105	12,757	204,510	Feb 23 08:04 PM
Lin Charles Y	SR VP, RESEARCH & DEVELOPMENT	Feb 21 '24	Sale	1.05	12,036	12,685	234,603	Feb 23 08:07 PM
Olek Elizabeth A	SR VP, CLINICAL SCIENCE	Feb 21 '24	Sale	1.05	7,368	7,765	193,275	Feb 23 08:12 PM
DiMartino Jorge	Chief Medical Officer & VP	Jan 04 '24	Sale	1.18	12,009	14,214	315,246	Jan 05 06:27 PM
Kosacz Barbara	COO & General Counsel	Jan 04 '24	Sale	1.18	10,676	12,636	928,966	Jan 05 06:26 PM
Dinsmore Christopher	Chief Scientific Officer	Jan 04 '24	Sale	1.18	7,366	8,718	260,969	Jan 05 06:30 PM
DiMartino Jorge	Chief Medical Officer & VP	Dec 12 '23	Sale	1.30	17,367	22,664	327,255	Dec 13 04:09 PM
Dinsmore Christopher	Chief Scientific Officer	Dec 12 '23	Sale	1.30	10,032	13,092	268,335	Dec 13 04:10 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 17 '23	Buy	1.08	97,935	106,162	2,540,665	Nov 17 05:41 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 16 '23	Buy	1.00	262,433	261,514	2,442,730	Nov 17 05:41 PM
BISCHOFBERGER NORBERT W	President & CEO	Nov 15 '23	Buy	0.80	1,370,688	1,102,718	2,180,297	Nov 17 05:41 PM
DiMartino Jorge	Chief Medical Officer & VP	Jul 06 '23	Sale	1.75	10,818	18,956	344,622	Jul 07 04:07 PM
Al-Wakeel Yasir B.	Chief Financial Officer	Jul 06 '23	Sale	1.75	9,617	16,852	346,102	Jul 07 04:06 PM
Dinsmore Christopher	Chief Scientific Officer	Jul 06 '23	Sale	1.75	6,634	11,625	278,367	Jul 07 04:08 PM

Open in Screener

GOSS

Gossamer Bio Inc

Apr 25 • 04:00PM ET

0.6700

Dollar change -0.0383
Percentage change -5.41	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VHT SCHA IWC SCHB

Index	-	P/E	-	EPS (ttm)	-1.38	Insider Own	16.27%	Shs Outstand	225.41M	Perf Week	-16.87%
Market Cap	151.14M	Forward P/E	-	EPS next Y	-0.70	Insider Trans	0.51%	Shs Float	188.87M	Perf Month	-45.53%
Income	-179.82M	PEG	-	EPS next Q	-0.19	Inst Own	79.45%	Short Float	5.88%	Perf Quarter	-16.16%
Sales	0.00M	P/S	-	EPS this Y	35.82%	Inst Trans	11.74%	Short Ratio	8.17	Perf Half Y	40.08%
Book/sh	0.28	P/B	2.41	EPS next Y	6.95%	ROA	-61.54%	Short Interest	11.11M	Perf Year	-40.18%
Cash/sh	1.31	P/C	0.51	EPS next 5Y	5.20%	ROE	-480.50%	52W Range	0.45 - 1.88	Perf YTD	-26.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.99%	ROI	-69.08%	52W High	-64.36%	Beta	1.84
Dividend TTM	-	Quick Ratio	5.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	48.07%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	5.94	EPS Y/Y TTM	49.48%	Oper. Margin	0.00%	RSI (14)	20.45	Volatility	12.53% 9.75%
Employees	135	Debt/Eq	3.38	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	5.72
Option/Short	Yes / Yes	LT Debt/Eq	3.15	EPS Q/Q	63.89%	Payout	-	Rel Volume	1.87	Prev Close	0.71
Sales Surprise	-	EPS Surprise	-0.82%	Sales Q/Q	-	Earnings	Mar 05 BMO	Avg Volume	1.36M	Price	0.67
SMA20	-30.21%	SMA50	-42.59%	SMA200	-31.76%	Trades		Volume	2,484,614	Change	-5.41%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Resumed	Wedbush	Outperform	$4
Jul-27-23	Downgrade	UBS	Buy → Neutral	$8 → $1.25
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral	$3
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight	$18 → $2
Oct-20-22	Initiated	Goldman	Buy	$22
Sep-21-22	Initiated	JP Morgan	Neutral	$17
Sep-19-22	Initiated	Wedbush	Outperform	$24
Apr-18-22	Initiated	Raymond James	Outperform	$19
Apr-06-22	Initiated	UBS	Buy	$19
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform	$24
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight	$20
Sep-21-21	Resumed	Piper Sandler	Overweight	$26
Jun-29-20	Initiated	H.C. Wainwright	Buy	$31
Apr-22-20	Initiated	Piper Sandler	Overweight	$30
Feb-27-20	Initiated	Barclays	Overweight	$21
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy	$31

Show Previous Ratings

Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 07:31AM	Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors (Business Wire)
Mar-07-24 09:55AM	Should You Buy Gossamer Bio (GOSS) After Golden Cross? (Zacks) -7.95%
Mar-05-24 10:52PM	GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Gossamer Bio Posts Narrower Loss In Q4 - Quick Facts (RTT News)
07:40AM	Loading…
07:40AM	Gossamer Bio: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-31-24 02:23PM	7 Micro-Cap Stocks That Could Majorly Surprise Investors (InvestorPlace)
Jan-22-24 10:53AM	5 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.24%
Dec-13-23 04:01PM	Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 (Business Wire)
Dec-05-23 04:01PM	Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31%
07:01AM	Gossamer Bio Appoints Bob Smith as Chief Commercial Officer (Business Wire)
Nov-29-23 07:01AM	Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors (Business Wire)
08:11AM	Loading…
Nov-09-23 08:11AM	Gossamer Bio Inc (GOSS) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -7.56%
07:41AM	Gossamer Bio: Q3 Earnings Snapshot (Associated Press Finance)
07:31AM	Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -6.46%
Oct-03-23 04:08PM	Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs (Business Wire) -5.57%
Sep-07-23 07:44AM	Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 (Business Wire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-08-23 04:41PM	Gossamer Bio: Q2 Earnings Snapshot (Associated Press Finance) -5.43%
04:01PM	Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-24-23 04:16PM	Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results (Business Wire)
Jul-20-23 07:56AM	Gossamer Bio Announces $212 Million Private Placement Financing (Business Wire) -31.87%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
May-18-23 07:05AM	Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference (Business Wire) +7.58%
May-13-23 08:15AM	In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
May-09-23 04:13PM	Gossamer Bio: Q1 Earnings Snapshot (AP Finance)
04:01PM	Loading…
04:01PM	Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Apr-04-23 12:38PM	After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate (Benzinga) -9.38%
Mar-17-23 07:46AM	Gossamer Bio: Q4 Earnings Snapshot (AP Finance) -8.47%
07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-07-23 03:37PM	Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success (Benzinga)
Mar-03-23 11:40AM	15 Most Shorted Stocks Right Now on Wall Street (Insider Monkey)
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace) +7.20%
Jan-04-23 12:00PM	Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.39%
09:35AM	Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Dec-26-22 09:41AM	Bullish insiders at Gossamer Bio, Inc. (NASDAQ:GOSS) loaded up on US$1.2m of stock earlier this year (Simply Wall St.)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga) -74.60%
10:00AM	Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation (Benzinga)
08:19AM	Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug (MarketWatch)
07:15AM	Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH (Business Wire)
Nov-17-22 02:37PM	Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial (Benzinga)
Nov-08-22 12:00PM	What Makes Gossamer Bio (GOSS) a New Buy Stock (Zacks)
Nov-03-22 04:01PM	Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Oct-24-22 08:30AM	Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential (TipRanks)
Aug-29-22 08:11AM	With 62% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners (Simply Wall St.)
Aug-09-22 08:01AM	Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Jul-21-22 06:21PM	2 Strong Buy Stocks That In-The-Know Bigwigs Are Pouring Money Into (TipRanks)
Jul-20-22 11:33AM	Squeezable AMC, GameStop stocks break out to multi-month highs (MarketWatch)
Jul-19-22 12:00PM	Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy (Zacks) +6.29%
09:46AM	The Co-Founder of Gossamer Bio, Inc. (NASDAQ:GOSS), Faheem Hasnain, Just Bought 3.8% More Shares (Simply Wall St.)
Jul-18-22 09:55AM	Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High? (Zacks)
Jul-13-22 07:15AM	Gossamer Bio Announces $120 Million Private Placement Financing (Business Wire) +31.90%
Jun-09-22 08:30AM	Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinibs Potential for the Treatment of PAH (Business Wire)
May-26-22 09:55AM	Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade (Zacks)
May-23-22 09:55AM	Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-10-22 04:01PM	Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update (Business Wire) +11.70%
May-06-22 12:20PM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.) -7.01%
Apr-25-22 07:29AM	Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update (Business Wire)
Mar-03-22 04:01PM	Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update (Business Wire)
Feb-28-22 07:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022 (Business Wire)
Jan-02-22 08:47AM	What Kind Of Investors Own Most Of Gossamer Bio, Inc. (NASDAQ:GOSS)? (Simply Wall St.)
Nov-08-21 04:01PM	Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Nov-02-21 04:01PM	Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021 (Business Wire)
Oct-11-21 08:36AM	Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208 (Business Wire) +6.52%
Oct-07-21 04:01PM	Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021 (Business Wire)
Oct-03-21 10:45AM	Is Gossamer Bio (NASDAQ:GOSS) Weighed On By Its Debt Load? (Simply Wall St.)
Sep-21-21 08:31AM	Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role (Business Wire) +10.63%
Aug-09-21 04:01PM	Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Aug-02-21 04:01PM	Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021 (Business Wire)
Jul-21-21 05:16AM	Hedge Funds Are Selling Gossamer Bio, Inc. (GOSS) (Insider Monkey)
Jul-17-21 05:47AM	Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Increased Their Holdings (Simply Wall St.)
Jul-07-21 07:01AM	Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohns and Colitis Organisation (Business Wire)
Jun-21-21 04:01PM	Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer (Business Wire)
Jun-14-21 04:01PM	Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors (Business Wire)
May-06-21 07:31AM	Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update (Business Wire)
Apr-20-21 07:50AM	Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer (Business Wire)
Apr-16-21 07:55AM	Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs (Business Wire)
Feb-25-21 07:31AM	Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update (Business Wire) -5.59%
Feb-19-21 08:01AM	Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021 (Business Wire)
Feb-04-21 07:05AM	Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021 (Business Wire)
Jan-18-21 03:05AM	Have Insiders Been Buying Gossamer Bio, Inc. (NASDAQ:GOSS) Shares This Year? (Simply Wall St.)
Dec-19-20 03:54PM	Is GOSS A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)
Dec-11-20 05:00PM	Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial (GlobeNewswire)
Dec-07-20 07:03AM	Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020 (Business Wire)
Nov-16-20 07:01AM	Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer (Business Wire)
Nov-10-20 04:01PM	Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update (Business Wire)
02:30PM	Gossamer Bio, Inc. to Host Earnings Call (ACCESSWIRE)
08:00AM	Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-20 07:07AM	Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020 (Business Wire)
07:03AM	Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting (Business Wire)
Oct-13-20 03:02PM	Hedge Funds Are Piling Into Gossamer Bio, Inc. (GOSS) (Insider Monkey) -25.75%
07:04AM	Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis (Business Wire)
Oct-12-20 08:07AM	Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates (Business Wire)
Oct-09-20 08:01AM	Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020 (Business Wire)
Sep-30-20 08:38AM	Are Options Traders Betting on a Big Move in Gossamer Bio (GOSS) Stock? (Zacks)
Sep-10-20 07:07AM	Gossamer Bio Announces Participation in Upcoming Investor Conferences (Business Wire)

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hasnain Faheem	President & CEO	Mar 27 '24	Sale	1.16	23,172	26,773	120,293	Mar 28 06:01 PM
Giraudo Bryan	COO/CFO	Mar 27 '24	Sale	1.16	6,430	7,431	92,737	Mar 28 06:05 PM
Christian Waage	EVP, Tech Ops and Admin	Mar 27 '24	Sale	1.16	6,430	7,430	585,934	Mar 28 06:16 PM
Peterson Caryn	EVP, Regulatory Affairs	Mar 18 '24	Sale	1.33	4,018	5,343	49,833	Mar 19 06:50 PM
Aranda Richard	Chief Medical Officer	Mar 18 '24	Sale	1.33	4,018	5,342	198,799	Mar 19 06:50 PM
Milligan Sandra	Director	Nov 15 '23	Buy	0.79	32,000	25,213	32,000	Nov 17 04:01 PM
Giraudo Bryan	COO/CFO	Nov 13 '23	Buy	0.56	200,000	112,880	380,010	Nov 14 06:24 PM
Aranda Richard	Chief Medical Officer	Jun 22 '23	Sale	1.29	1,814	2,340	197,574	Jun 26 04:01 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

MORF

Morphic Holding Inc

KRON

Kronos Bio Inc

GOSS

Gossamer Bio Inc

Upgrade your FINVIZ experience